NCT04747197View on ClinicalTrials.gov

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

EYP-1901

Intravitreal injection

Trial Locations (11)

19107

EyePoint Investigational Site, Philadelphia

28803

EyePoint Investigative Site, Asheville

32901

EyePoint Investigational Site, Melbourne

33711

EyePoint Investigational Site, St. Petersburg

78705

EyePoint Investigational Site, Austin

79606

EyePoint Investigational Site, Abilene

85053

EyePoint Investigational Site, Phoenix

90211

EyePoint Investigational Site, Beverly Hills

93036

EyePoint Investigational Site, Oxnard

94040

EyePoint Investigative Site, Mountain View

01107

EyePoint Investigational Site, Springfield

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY